{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:58:19Z","timestamp":1789379899657,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.critrevonc.2015.08.020","type":"journal-article","created":{"date-parts":[[2015,8,29]],"date-time":"2015-08-29T13:20:50Z","timestamp":1440854450000},"page":"263-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays"],"prefix":"10.1016","volume":"97","author":[{"given":"Ayda","family":"Bennour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima","family":"Sennana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2015.08.020_bib0005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1600-0609.2008.01170.x","article-title":"Correlation of BCR\/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia","volume":"82","author":"Adler","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cancergencyto.2006.09.025","article-title":"\u201cHome-brew\u201d FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia","volume":"174","author":"Albano","year":"2007","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cancergencyto.2004.02.012","article-title":"Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis","volume":"154","author":"Aoun","year":"2004","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"issue":"35","key":"10.1016\/j.critrevonc.2015.08.020_bib0025","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"European LeukemiaNet:Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0030","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0035","first-page":"413","article-title":"Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood","volume":"64","author":"Bennett","year":"1845","journal-title":"Edinb. Med. Surg. J."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cancergencyto.2007.11.007","article-title":"A masked BCR\/ABL rearrangement in a case of chronic myeloid leukemia with translocation t(3;9)(p14;q34)","volume":"181","author":"Bennour","year":"2008","journal-title":"Cancer Genet. Cytogenet."},{"issue":"1","key":"10.1016\/j.critrevonc.2015.08.020_bib0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cancergencyto.2009.05.010","article-title":"Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9","volume":"194","author":"Bennour","year":"2009","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0050","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/jcp.2010.078311","article-title":"E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib","volume":"63","author":"Bennour","year":"2010","journal-title":"J. Clin. Pathol."},{"issue":"September 9","key":"10.1016\/j.critrevonc.2015.08.020_bib0055","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00432-011-1002-4","article-title":"Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients","volume":"137","author":"Bennour","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0060","first-page":"433","article-title":"Comprehensive analysis of BCR\/ABL variants in chronic myeloid leukemia patients using multiplex RT-PCR","volume":"58","author":"Bennour","year":"2012","journal-title":"Clin. Lab."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0065","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s12032-011-9918-8","article-title":"Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients","volume":"29","author":"Bennour","year":"2012","journal-title":"Med. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0070","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12032-012-0348-z","article-title":"Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia","volume":"30","author":"Bennour","year":"2013","journal-title":"Med. Oncol."},{"issue":"March (1)","key":"10.1016\/j.critrevonc.2015.08.020_bib0075","first-page":"47","article-title":"A novel t(3;12)(q21;p13) translocation in a patient with accelerated chronic myeloid leukemia after imatinib and nilotinib therapy","volume":"10","author":"Bennour","year":"2013","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0080","first-page":"20","article-title":"Cytogenetics of chronic myelogenous leukemia","volume":"25","author":"Bernstein","year":"1988","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0085","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate- binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0090","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1073\/pnas.92.7.2558","article-title":"Selective inhibition of the platelet-derived growth factor signal transduction pathway by protein tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class","volume":"92","author":"Buchdunger","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0095","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","article-title":"Emergence of clonal cytogenetic abnormalities in Ph-cells in some CMLpatients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority","volume":"101","author":"Bumm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cancergencyto.2007.06.013","article-title":"Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia","volume":"178","author":"Campos","year":"2007","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0105","first-page":"1241","article-title":"Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features?","volume":"10","author":"Cervantes","year":"1996","journal-title":"Leukemia."},{"issue":"November (19)","key":"10.1016\/j.critrevonc.2015.08.020_bib0110","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1038\/sj.onc.1201400","article-title":"The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells","volume":"15","author":"Cortez","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0115","first-page":"803","article-title":"Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia","volume":"4","author":"De Lemos","year":"2005","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0120","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0125","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/cncr.22936","article-title":"The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells","volume":"110","author":"Deininger","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0130","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/asheducation-2008.1.419","article-title":"Milestones and monitoring in patients with CML treated with imatinib","volume":"1","author":"Deininger","year":"2008","journal-title":"Am. Soc. Hematol. Educ. Program Hematol."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0140","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0145","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2141.2004.04899.x","article-title":"Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome","volume":"125","author":"El-Zimaity","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0150","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2403562","article-title":"WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature","volume":"19","author":"Elliott","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0155","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/sj.leu.2403861","article-title":"Induction of centrosome and chromosome aberrations by imatinib in vitro","volume":"19","author":"Fabarius","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0160","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2015.08.020_bib0165","first-page":"169","article-title":"Chronic myelogenous leukemia: update on biology and treatment","volume":"13","author":"Faderl","year":"1999","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0170","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/cncr.11664","article-title":"The biology and therapy of adult acute lymphoblastic leukemia","volume":"98","author":"Faderl","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0175","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cancergencyto.2005.01.002","article-title":"Deletionsof the 30 BCR and 50 ABL regions in patients with Philadelphia positive chronic myeloid leukemia: a one-step process occurring in about 10% of the cases without any evidence of genetic instability in the target cells","volume":"160","author":"Fournier","year":"2005","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0180","doi-asserted-by":"crossref","first-page":"173e5","DOI":"10.1016\/j.cancergencyto.2005.05.010","article-title":"Masked Philadelphia chromosome due to atypical BCR\/ABL localization on the 9q34 band and duplication of the der (9) in a case of chronic myelogenous leukemia","volume":"163","author":"Fugazza","year":"2005","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0185","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Gabert","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0190","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.trsl.2006.07.002","article-title":"Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR","volume":"148","author":"Goh","year":"2006","journal-title":"Transl. Res."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0195","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cancergencyto.2006.10.006","article-title":"On the genesis and prognosis of variant translocations in chronic myeloid leukemia","volume":"173","author":"Gorusu","year":"2007","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0200","article-title":"Fluorescence in situ hybridization characterization of different cryptic BCR\/ABL rearrangements in chronic myeloid leukemia. [Erratum in: Cancer Genet Cytogenet 2005;156:188-9]","volume":"155","author":"Haigh","year":"2004","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0205","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. German CML study Group","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.08.020_bib0210","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4238\/2012.February.10.2","article-title":"Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia","volume":"11","author":"Hsiao","year":"2012","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0215","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCRABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0220","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2002-09-2763","article-title":"Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions","volume":"102","author":"Huntly","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0225","article-title":"An international system for human cytogenetic nomenclature","author":"ISCN","year":"2009"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0230","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1182\/blood.V78.12.3125.3125","article-title":"A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia","volume":"78","author":"Inokuchi","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0235","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1182\/blood.V78.12.3125.3125","article-title":"A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia","volume":"78","author":"Inokuchi","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0240","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0245","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-01-070045","article-title":"Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0250","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7326\/0003-4819-122-4-199502150-00003","article-title":"Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The leukemia service","volume":"122","author":"Kantarjian","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0255","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1751-553X.2007.00991.x","article-title":"Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia","volume":"30","author":"Kim","year":"2008","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0260","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/blood.V97.11.3581","article-title":"Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis","volume":"97","author":"Kolomietz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0265","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2006-04-017400","article-title":"Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia","volume":"108","author":"Kovitz","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0270","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1056\/NEJM198810133191506","article-title":"The molecular genetics of Philadelphia chromosome-positive leukemias","volume":"319","author":"Kurzrock","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0275","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cancergencyto.2005.08.028","article-title":"Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia","volume":"166","author":"Lee","year":"2006","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0280","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cancergencyto.2006.04.012","article-title":"Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors","volume":"170","author":"Lin","year":"2006","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0285","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/gcc.10056","article-title":"Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9) t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia","volume":"34","author":"Loncarevic","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0290","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0295","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0300","first-page":"666","article-title":"Younger age and shorter chronic phase in b2a2-positive chronic myeloid leukemia adults with high white blood cell count at diagnosis","volume":"87","author":"Mart\u0131\u0301nez-Mancilla","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0305","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1128\/MCB.9.5.1866","article-title":"Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells","volume":"9","author":"McLaughlin","year":"1989","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0310","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0315","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0320","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ajh.20682","article-title":"Molecular profiling of chronic myeloid leukemia in eastern India","volume":"81","author":"Mondal","year":"2006","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0325","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1136\/jcp.2005.029595","article-title":"e19a2 BCR-ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases","volume":"59","author":"Mondal","year":"2006","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0330","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0165-4608(03)00204-8","article-title":"Contribution of FLuorescence in situ hybridization analyses to the characterization of masked and complex Philadelphia chromosome translocation in chronic myelocytic leukemia","volume":"147","author":"Morel","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0335","doi-asserted-by":"crossref","first-page":"107884","DOI":"10.1182\/blood.V78.4.1078.1078","article-title":"gene is joined to 50- BCR in some patients with Philadelphia-positive leukemia","volume":"78","author":"Morris","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0340","first-page":"69","article-title":"Uber myelogene leukemia","author":"Neumann","year":"1878","journal-title":"Berliner Klinishe Wochenschreibe"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0345","first-page":"1497","article-title":"A minute chromsome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0350","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/0145-2126(92)90039-A","article-title":"No correlation between site of breakpoint in the BCR gene and platelet counts in Philadelphia chromosome-positive CML","volume":"16","author":"Opalka","year":"1992","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0355","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood.V88.7.2410.bloodjournal8872410","article-title":"Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR\/ABL with C3\/A2 junction)","volume":"88","author":"Pane","year":"1996","journal-title":"Blood"},{"issue":"October (1)","key":"10.1016\/j.critrevonc.2015.08.020_bib0360","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","article-title":"BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein","volume":"75","author":"Pendergast","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0365","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0959-8049(00)00128-3","article-title":"The possible influences of B2A2 and B3A2 BCR\/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia","volume":"36","author":"Perego","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0370","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2004-06-2208","article-title":"Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia","volume":"105","author":"Quintas-Cardama","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0375","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0165-4608(99)00187-9","article-title":"A FISH study of variant Philadelphia rearrangements","volume":"118","author":"Reddy","year":"2000","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0380","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0385","first-page":"1104","article-title":"Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia","volume":"9","author":"Rozman","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0390","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1399-0004.2005.00521.x","article-title":"Evidence for deletion of 9q as a two-step process in chronic myeloid leukemia","volume":"68","author":"Rudduck-Sivaswaren","year":"2005","journal-title":"Clin. Genet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0395","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","article-title":"Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients","volume":"86","author":"Sacchi","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0400","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood.V76.9.1819.1819","article-title":"New type of Bcr\/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"76","author":"Saglio","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0405","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1038\/sj.leu.2403079","article-title":"BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis","volume":"17","author":"Schultheis","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0410","first-page":"35e9","article-title":"Complex chromosome rearrangements may locate the bcr\/abl fusion gene sites other than 22q11","volume":"85","author":"Sessarego","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0415","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-009-0822-7","article-title":"Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts","volume":"89","author":"Sharma","year":"2010","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0420","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood.V95.3.738.003k21_738_743","article-title":"Large deletions at the t(9;22) breakpoint are common and may identify a poor prognosis subgroup of patients with chronic myeloid leukemia","volume":"95","author":"Sinclair","year":"2000","journal-title":"Blood"},{"issue":"October 20","key":"10.1016\/j.critrevonc.2015.08.020_bib0425","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","article-title":"Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway","volume":"16","author":"Skorski","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0430","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cancergencyto.2008.01.005","article-title":"Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL or BCR deletion status or response to imatinib therapy","volume":"182","author":"Soenen","year":"2008","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0435","doi-asserted-by":"crossref","first-page":"141e5","DOI":"10.1016\/S0165-4608(02)00530-7","article-title":"Molecular cytogenetic characterization of a complex rearrangement involving chromosomes 9 and 22 in a case of Phnegative chronic myeloid leukemia","volume":"136","author":"Storlazzi","year":"2002","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0440","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cancergencyto.2004.01.019","article-title":"Effect of interferon-alpha on chromosome abnormalities in treated chronic myelogenous leukemia patients","volume":"153","author":"Tanaka","year":"2004","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0445","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.leu.2403399","article-title":"Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia","volume":"18","author":"Terre","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.cancergencyto.2005.11.008","article-title":"A Ph-negative chronic myeloid leukemia with a complex BCR\/ABL rearrangement and a t(6;9)(p21;q34. 1)","volume":"166","author":"Todori\u0107-Zivanovi\u0107","year":"2006","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0455","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukaemia for detection of minimal residual disease. Report of the BIOMOED-1Concerted Action: investigation of minimal residual disease in acute leukaemia","volume":"13","author":"Van Dongen","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0460","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/1097-0142(19950915)76:6<992::AID-CNCR2820760612>3.0.CO;2-L","article-title":"The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations","volume":"76","author":"Verschraegen","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0465","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1002\/cncr.10490","article-title":"Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR\/ABL mRNA and undetectable BCR\/ABL protein may predict an indolent course","volume":"94","author":"Verstovsek","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0470","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.leu.2404635","article-title":"High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations","volume":"21","author":"Vivante","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0475","first-page":"2","article-title":"Atypical in situ fluorescence in situ hybridisation pattern in chronic myeloid leukaemia due to crypticinsertion of BCR at 9q34","author":"Wan","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0480","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0092-8674(84)90228-9","article-title":"The mouse c-abl locus: molecular cloning and characterization","volume":"36","author":"Wang","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0485","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/gcc.1171","article-title":"Chronic myelogenous leukemia: laboratory diagnosis and monitoring","volume":"32","author":"Wang","year":"2001","journal-title":"Genes Chromosome Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0490","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","article-title":"Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABLtransformed hematopoietic cell lines","volume":"95","author":"Weisberg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0495","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cancergencyto.2005.07.012","article-title":"Coexistence of Philadelphia chromosome positive cells with and without der(9) deletion in a patient with chronic myelogenous leukemia","volume":"164","author":"Xinh","year":"2006","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0500","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2141.1993.tb03062.x","article-title":"The type of BCR\/ABL junction does not predict the survival of patients with Ph1-positive chronic myeloid leukaemia","volume":"84","author":"Zaccaria","year":"1993","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0505","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cancergencyto.2003.08.018","article-title":"A Fluorescence in situ hybridization study of complex t(9;22) in two chronic myelocytic leukemia cases with a masked Philadelphia chromosome","volume":"150","author":"Zagaria","year":"2004","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2015.08.020_bib0510","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cancergencyto.2006.01.011","article-title":"Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia","volume":"167","author":"Zagaria","year":"2006","journal-title":"Cancer Genet. Cytogenet."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815300354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815300354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T20:36:44Z","timestamp":1718051804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815300354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":102,"alternative-id":["S1040842815300354"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.08.020","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}